October 1999

Methotrexate as an Adjuvant Treatment for Pemphigus Vulgaris

Author Affiliations

Not Available


Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

Arch Dermatol. 1999;135(10):1275-1276. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-10-dlt1099

Conventional adjuvant treatments do not consistently permit steroid therapy to be discontinued in patients with chronic pemphigus vulgaris (PV).1,2 Methotrexate therapy, which was reported to be effective,3,4 has been largely abandoned because of concerns about toxic effects.1,2 This might have resulted from the high dosages (up to 150 mg/wk) of methotrexate used together with high dosages of steroids. We describe the efficacy of low dosages of methotrexate in patients taking low to moderate dosages of steroids.

First Page Preview View Large
First page PDF preview
First page PDF preview